Compare BNZI & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | CDT |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 3.4M |
| IPO Year | N/A | N/A |
| Metric | BNZI | CDT |
|---|---|---|
| Price | $1.15 | $1.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 499.4K | 410.7K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,650,176.00 | N/A |
| Revenue This Year | $223.24 | N/A |
| Revenue Next Year | $31.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.06 | N/A |
| 52 Week Low | $1.09 | $1.48 |
| 52 Week High | $27.00 | $2,198.40 |
| Indicator | BNZI | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 34.70 | 44.05 |
| Support Level | $1.14 | $1.69 |
| Resistance Level | $1.37 | $2.33 |
| Average True Range (ATR) | 0.12 | 0.25 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 11.76 | 31.76 |
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
CDT Equity Inc, formerly Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.